We describe incidence, clinical features, serological data, response to therapy and outcome of autoimmune cytopenias (ACs), including autoimmune hemolytic anemia (AIHA) and autoimmune thrombocytopenia (AIT) in a series of 281 consecutive adults with hematological malignancies that received single-unit umbilical cord blood transplantation (UCBT) at a single institution. AIHA was diagnosed in 15 patients at a median time of 181 days (range, 25-543), 12 of them had cold antibodies (IgM). The 3-year cumulative incidence (CI) of AIHA was 5.4% (CI 95% 2.7-8.1). Concomitant infections at the time of AIHA were present in 10 patients. Five out of nine patients that received corticosteroids achieved either a PR or a CR, whereas six out of eight patients that received rituximab responded. Four patients developed AIT giving a 3-year CI of 1.4% (CI 95% 0-2.8), concomitant infections were present in three of them. Multivariable analysis showed that development of chronic GVHD (relative risk (RR) 4; 95% CI 1.1-13.7; P = 0.03) and diagnosis of CML (RR 4.3; 95% CI 1.5-12.7; P = 0.008) were associated with an increased risk of AC. In conclusion, AIHA and AIT are relevant and clinically significant complications in UCBT recipients, especially among those that develop chronic GVHD. Response to therapy is sub-optimal, and rituximab should be considered as a therapeutic option, in this setting were most patients had cold AIHA and a serological profile similar to that seen in cold agglutinin disease.
INTRODUCTION
Umbilical cord blood has been increasingly used as a stem cell source for transplantation. Differences with other stem cell sources have been described such as a decreased rate of GVHD, mainly owing to a capacity to tolerate a higher degree of HLA disparity, and a somewhat slower immune reconstitution after transplantation. However, there is still much to know about other immune-related complications and the mechanisms by which immune tolerance is achieved.
Autoimmune hemolytic anemia (AIHA) and autoimmune thrombocytopenia (AIT) are increasingly recognized complications after allogeneic hematopoietic SCT (HSCT). These autoimmune disorders have been previously related to the use of unrelated donors and development of GVHD, probably reflecting a dysregulation of the immune system in these settings. 1, 2 These autoimmune cytopenias (ACs) have been recently described among patients undergoing umbilical cord blood transplantation (UCBT), in case reports and in a registry-based study that analyzed autoimmune disorders in a cohort of patients with malignant and non-malignant diseases in both children and adults. 3 The aim of the present study was to analyze the incidence of AC, as well as to describe the presenting clinical features, specific serological data, response to therapy and outcome in a large series of adult patients that received single-unit UCBT at a single institution.
PATIENTS AND METHODS Patients
All consecutive adult patients with diverse hematological malignancies undergoing single-unit UCBT from unrelated donors at Hospital Universitario La Fe between May 1997 and December 2012 were included in the study. The institutional review board approved the protocol and written informed consent was obtained from all patients according to the Declaration of Helsinki.
The treatment plans including graft selection, conditioning regimen, immune suppression and supportive care have been reported in detail previously, [4] [5] [6] and are summarized below. ) and ATG (Thymoglobulin 6-8 mg/kg). Patients considered unfit to receive a MAC were treated with a reduced intensity conditioning regimen that included thiotepa (5 mg/kg), fludarabine (150 mg/m 2 ), CY (50 mg/kg) or i.v. BU as a single dose (6.4 mg/kg) and ATG (Thymoglobulin 6-8 mg/kg).
Conditioning regimens

GVHD prophylaxis and treatment
All patients received cyclosporine 1.5 mg/kg/12 h i.v., followed by 3-5 mg/kg/12 h PO when oral intake was possible, with slow tapering starting between day +90 and +180 and discontinuation on day +180 or before, if feasible. According to the period of transplantation, cyclosporine was combined with a long course of prednisone (0.5 mg/kg/day on days +7 to +14, 1 mg/kg/day on days +14 to +28, with slow tapering until discontinuation on day +180), mycophenolate-mofetil (15 mg/kg/12 h until day +28) or a short course of prednisone (1 mg/kg/day on days +14 to +28). Patients developing acute GVHD received high-dose methylprednisolone as initial therapy (20 mg/kg/day; halving the dose every 3 days until reaching 1 mg/kg/day, and then gradually tapered). Chronic GVHD was treated with prednisone (1 mg/kg/day for a minimum of 14 days followed by a gradual taper).
Serologic tests
ABO group typing and antibody screening tests were performed on donor and recipient samples before transplantation and whenever patients required a RBC transfusion. The direct antiglobulin test (DAT) was performed as part of the routine pre-transfusion compatibility testing and in all patients with clinical suspicion of hemolytic anemia. The test was performed on RBC samples using polyspecific antihuman globulin (Organon Teknika, Durham, NC, USA) according to standard methods. 7 If this DAT was positive, further testing with specific anti-IgG (IgG, Ortho Clinical Diagnostics, Buckinghamshire, UK) and anti-C3d reagents (Biotest AG, Dreieich, Germany) was carried out. RBC eluates were prepared and tested by acid elution (Elu-Kitt II, Gamma Biologicals, Houston, TX, USA) or chloroform techniques. 8 Eluates and sera of patients with positive screening tests or positive DAT were tested for specificity and titration using panels of RBC with known antigens (Ortho Clinical and Diagnostics, Raritan, NJ, USA, Diamed and Makropanel), at room temperature and at 37°C. Absorption techniques were performed to exclude any underlying alloantibody. The IgG and IgM components of the antibodies were determined by testing sera before and after treatment with dithiothreitol.
Definitions
AIHA was diagnosed in patients fulfilling all of the following criteria: positive DAT, positive indirect antiglobulin test with broad reactivity to RBC in serum and eluate, clinical and laboratory evidence of hemolysis (increased lactate dehydrogenase and bilirubin levels, decreased Hb and haptoglobin levels and increased transfusion requirements) and exclusion of other causes of hemolysis. AIT was a diagnosis of exclusion, defined accordingly to previously standardized criteria as isolated thrombocytopenia (platelet count below 100 × 10 9 /L) in the absence of other causes or disorders that may be associated with a low platelet count. 9 All patients included in the present series had full donor chimerism at the time of diagnosis of AIHA or AIT.
CR to treatment for AIHA was defined as the resolution of all clinical and laboratory signs of hemolysis and with no detectable antibody in serum, eluate or on the RBC surface. PR was defined as the persistence of detectable autoantibody with an improvement of laboratory data or a decrease in transfusion requirements. Patients not fulfilling the previous definitions were considered to have no response. The response to therapy among patients with AIT was assessed according the criteria suggested by the International Working Group (IWG). 9 
Statistical analysis
The probability of development of AIHA or AIT was estimated by the cumulative incidence (CI) method (marginal probability), and for comparisons the Gray test was used. 10, 11 For CI analyses, relapse and death without AC were considered as a competing cause of failure. The Fine and Gray 11 method for competing events was used for multivariable analysis using variables with a P-value o0.10 for each end point. Variables included in the model were: conditioning regimen (MAC vs reduced intensity conditioning), diagnosis, age, gender, recipient CMV serostatus, disease stage at transplantation, HLA compatibility considering lowresolution typing for class I and high-resolution typing for class II antigens, ABO compatibility, GVHD prophylaxis, total nucleated cell and CD34 + cell count before freezing and infusion and chronic GVHD as a time-dependent variable. Statistical analysis was conducted using R version 2.12. .
At the onset of AIHA, median values of laboratory parameters were: Hb 8 g/dL (range, 4-11), lactate dehydrogenase 800 U/L (range, 450-10 800), indirect bilirubin 2 mg/dL (range, 1,2-3) and haptoglobin 10 mg/dL (range, 0-69). Thirteen patients required transfusion support and received a median of 27 packed RBCs (range, 2-113). Because of rounding percentages may not add 100%.
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Characteristics of patients that developed AIHA are shown in Table 2 . All patients were in complete remission and had complete donor chimerism at time of diagnosis. Thirteen patients had concomitant GVHD at time of AIHA. Three out of four patients with early AIHA had acute GVHD (grade IV in two patients and grade II in the other one). Of the remaining 11 patients, 10 had chronic GVHD (extensive in nine of them). Concomitant infections at the time of AIHA were present in 10 patients. Five patients had a CMV reactivation, including three cases of polymicrobial infection (Pseudomonas aeruginosa bacteremia, disseminated tuberculosis and Human Herpesvirus-6 encephalitis). Two patients had pneumonitis due to respiratory syncytial virus (RSV), whereas the remaining three had other infections.
Serological data. Minor ABO mismatch between donor and recipient was present in five patients, whereas major mismatch was present in one patient. Twelve patients developed AIHA by cold antibodies (IgM), whereas the remaining three had warm antibody (IgG) disease. There was no association between time of appearance of AIHA and type of antibody. No antibodies against the ABO system were found in these patients.
Treatment and outcome. All patients with AIHA were treated except for one patient with ALL who subsequently relapsed and received palliative care. Prednisone or methylprednisolone (at doses ranging from 1 to 2 mg/kg/day) were administered as firstline therapy in eight patients. Of these, one achieved a CR, four had a PR and three had no response. Rituximab (375 mg/m 2 /week per four doses) was the first-line therapy in four patients; two of them had a CR, one had a PR and one had no response. Intravenous immunoglobulin (1 g/kg/day per two doses) was the first treatment administered in the remaining two patients, both of them achieved a PR. Six patients needed further therapy beyond the first line, including two cases that were treated with splenectomy (one patient had a CR, whereas the other had no response) and four cases that received rituximab (achieving PR in all of them). Ten patients died during follow-up, and uncontrolled infections were the cause of death among six of them. Only one patient died of refractory hemolysis despite treatment with high-dose corticosteroids, rituximab, plasmapheresis and splenectomy.
AIT Incidence and characteristics of AIT. Four patients developed AIT at 121, 259, 281 and 381 days after UCBT. Three-year CI of AIT was 1.4% (CI 95% 0-2.8). Two patients had chronic GVHD at the time of AIT diagnosis and another one subsequently developed it 6 months later. Concomitant infections were present in three patients; there was one case each of CMV reactivation, respiratory syncytial virus pneumonitis and herpes simplex gingivostomatitis.
Treatment and outcome. All patients received specific therapy. One patient received prednisone (1 mg/kg/day) and achieved a sustained CR. The remaining three patients received first-line therapy with i.v. immunoglobulin (1 g/kg/day per two doses) and achieved a temporary response with increase of the platelet count. All of them needed further therapy. One patient received prednisone obtaining a CR. The remaining two patients received rituximab (375 mg/m 2 /week per four doses), one achieved CR and the other one a response. Two patients are alive, the remaining two patients died of complications associated with chronic GVHD and relapse of AML.
Prognostic factors for AC Overall CI of AC at 3 years was 6.8% (95% CI; 3.8-9.8). The following variables were significantly associated with a higher incidence of AC at 3 years on univariable analysis: chronic GVHD vs no GVHD (12.7% vs 2.5%, P = 0.001) and baseline diagnosis of CML vs other diagnosis (18.5% vs 5.6%, P = 0.01). Development of chronic GVHD (relative risk 4; 95% CI 1.1-13.7; P = 0.03) and diagnosis of CML (relative risk 4.3; 95% CI 1.5-12.7; P = 0.008) remained as independent prognostic factors associated with an increased risk of AC in the multivariable analysis.
DISCUSSION
The present study shows that AIHA and AIT are relatively frequent complications after UCBT in adults with hematological malignancies. These disorders are closely related to the presence of chronic GVHD and various infections. Response to therapy was Abbreviations: AIHA = autoimmune hemolytic anemia; HHV-6 = human herpes virus-6; IFI = invasive fungal infection; MM = multiple myeloma; Rh = rhesus; RSV = respiratory syncytial virus.
Autoimmune cytopenias after UCBT J Sanz et al disappointing and overall mortality was high, although mostly associated with concomitant complications. Most cases of AIHA had cold antibodies (IgM) and may impact the choice of therapy. Our findings could help to increase awareness toward these complications and guide therapy in the UCBT setting. This study included a large group of adults with a variety of hematological malignancies that received UCBT at a single institution using a relatively homogeneous conditioning strategy, GVHD prophylaxis and supportive care, as well as monitoring for autoimmune complications. We used widely accepted and consistent definitions of AIHA and AIT, which were clinically relevant, in order to increase the external validity of our findings. The close serological monitoring carried out in our patients may have improved the sensitivity to detect incidental cases. However, the number of events was low making the analysis of prognostic factors difficult, which should therefore be interpreted cautiously.
We found a CI of AIHA of 5.4%, similar to what has been previously reported by our group and others after BM or peripheral blood SCT. 2, 13, 14 Only in the study by Page et al., 15 a substantially higher frequency was reported; however, this study focused on very young infants that were transplanted for nonmalignant diseases. These two factors were recently associated with an increased risk of autoimmune disorders after UCBT. However, this recent registry-based study described an apparently lower incidence of AC among the subgroup of adults with hematological malignancies. 3 In this regard, a single-center study using strict and careful case definitions may more reliably reflect the true incidence of this complication in a real-world scenario. Four patients developed AIT, although the incidence of this complication could have been underestimated owing to the fact that prolonged thrombocytopenia with poor graft function is frequent after UCBT and that AIT is mostly a diagnosis of exclusion. Information about this complication in the SCT setting is very limited, and is represented mostly by case reports that usually describe patients with concomitant AIHA (that is, EvansŚ yndrome). 16, 17 The impact of double-unit UCBT on the development of AC should be considered and further explored. Although we could not find a report that specifically addresses this issue, the pattern of immune reconstitution after double-unit UCBT has been recently described. 18 A delay in regulatory T-cell reconstitution alongside a fast B-cell engraftment was noted. These findings could increase the risk of autoimmune disorders among UCBT recipients.
Regarding serological data, most patients (80%) had IgMmediated cold antibody AIHA with specificity against the I antigen. No association between the period of AIHA diagnosis and the serological specificity of the antibodies was noticed. This is surprising and seems to be different to what was previously reported. In fact, most series have described a predominance of IgG warm antibodies directed against antigens of the rhesus system, 14, 19, 20 whereas Chen et al. 13 suggested that the presence of IgM antibodies was restricted to AIHA with early onset. We do not have a definite explanation for the above mentioned findings, but they could be due to a delayed and singular humoral reconstitution after UCBT compared with that seen with BMT.
Overall prognosis was poor, and although most patients died of concomitant infectious complications, massive uncontrolled hemolysis was the cause of death in one patient with warm AIHA who did not respond to several lines of treatment, including splenectomy. Despite aggressive therapy, a similar clinical behavior was recently reported by Rovira et al. 21 in two patients that received single-unit UCBT. In cases of sudden drop in Hb or an increase in transfusion requirements, the diagnosis of AIHA should be considered early. Most patients with AIHA failed to respond to corticosteroids and needed further treatment. Rituximab was a useful therapeutic strategy in our series, as seven out of eight patients responded. Very good responses have also been reported among patients with cold agglutinin disease. 22, 23 Rituximab should therefore be considered early in the management of AIHA after UCBT. Among patients with AIT, there were three transient responses to i.v. immunoglobulin, reinforcing the diagnosis. However, responses were of short duration and two patients were successfully treated later with rituximab, whereas the other one received long-term therapy with prednisone.
Concomitant infections were frequently observed at the time of diagnosis of AC. An intriguing possibility is that some of these infections could have triggered an abnormal immune response. In this regard, the danger model of autoimmunity suggests that signals of damaged cells after exposure to infectious agents can bind to APCs and activate a systemic immune response. 24 The development of AC was strongly associated with the presence of chronic GVHD. In fact, 12 of 19 patients had chronic GVHD at the time of diagnosis. This association has already been reported. 2, 3 It is known that chronic GVHD is associated with an abnormal immune function and predisposes to autoimmune disorders. 25 This finding supports the inclusion of AC as manifestations of chronic GVHD, as has been proposed by the National Institutes of Health consensus criteria. 26 In addition, baseline diagnosis of CML was an independent risk factor associated with an increased risk of AC. A high frequency of AIHA has been previously observed after T-cell-depleted allogeneic BMT for CML, 19 however, this finding has not been reported previously among UCBT recipients.
In conclusion, AIHA and AIT are relevant and clinically significant complications in UCBT recipients, especially among those that develop GVHD. Response to standard therapy for AC is suboptimal, and rituximab should be considered as a therapeutic option in this setting where most patients had cold AIHA and a serological profile similar to that seen in cold agglutinin disease. Finally, prognosis was poor and mainly associated with concomitant complications.
